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ABSTRACT: Chromomycin A3 ( C H R ) binding to t h e duplex d(CAAGTCTGGCCATCAGTC)-

d(GACTGATGGCCAGACTTG) has been studied using quantitative footprinting methods. Previous
N M R studies indicated C H R binds as a dimer in the minor groove. Analysis of autoradiographic spot
intensities derived from DNase I cleavage of the 18-mer in the presence of various amounts of C H R revealed
that the drug binds as a dimer to the sequence 5’-TGGCCA-3’, 3’-ACCGGT-5’ in the 18-mer with a binding
constant of (2.7 f 1.4) X lo7 M-l. Footprinting and fluorescence data indicate that the dimerization
constant for the drug in solution is -lo5 M-l. Since it has been suggested that C H R binding alters DNA
to the A configuration, quantitative footprinting studies using dimethyl sulfate, which alkylates at N-7 of
guanine in the major groove, were also carried out. Apparently, any drug-induced alteration in DNA
structure does not affect cleavage by DMS enough to be observed by these experiments.

ChromomycinA3 (CHR),’ Figure 1 (top panel), isa member
of the aureolic acid class of anticancer drugs, which includes
olivomycin and mithramycin (Miyamotoet al., 1967;Tatsuoka
et al., 1960). On the molecular level these drugs exert their
cytotoxic effects by binding to DNA, thereby interrupting
transcription (Baguley, 1982). The binding process is facilitated by Mg2+ and the interaction is believed to occur in the
minor groove of DNA (Brikenshtein et al., 1983; Prasad &
Nayak, 1976; Ward et al., 1965).
Chromomycin and mithramycin have been the subject of
numerous footprintingstudies. Van Dyke and Dervan (1983)
used the chemical cleavage agent Fe-MPE to show that CHR
is able to recognize guanine- and cytosine-rich sites that are
at least 3 base pairs in length. The affinity of sites was found
to decrease in the order 5’-GGG, AGC > GCC, CCG > AGC,
TCC, GTC-3’. The sequence AGC was found to have varying
affinities, indicating the importance of flanking bases or the
presence of nearby bound drug molecules. Strong binding of
CHR to GC-rich sites was also observed in DNase I
footprinting experiments (Fox & Howarth, 1985). As well
as inhibiting DNase I cleavage within a binding site, CHR
was found to enhance cleavage in AT-rich regions of DNA,
where no drug binding takes place. The enhancements were
attributed to DNA structural variations induced by the drug
in the vicinity of its binding site. The study also showed that
the reaction of dimethyl sulfate at N7 of guanine located in
the major groove of DNA is modified in the presence of
mithramycin. This prompted the authors to suggest that the
drug may be binding in the major groove of DNA.
Photofootprinting studies with U0z2+ indicated that mithramycin binds to GC-rich regions of DNA (Nielsen et al.,
1990). Areas surrounding drug binding sites showed enhanced
cleavage, stlggesting that mithramycin is able to distort local
DNA structure upon binding.
Footprinting aiialysis of DNA fragments having (AT),,
inserts (Cons & Fox, 1990) suggested that, when the inserts
are adjacent to mithramycin binding sites, bound drug causes
t We acknowledgethe American Cancer Society, Grant NP-68 1, for
support of this research.
Abbreviations: CHR,chromomycinA,; Fe-MPE,methidiumpropylEDTA-iron; DMS, dimethylsulfate;TEAA, triethylammoniumacetate;
TE, 10 mM Tris.HC1 and 1 mM EDTA, pH 7.6.
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FIGURE1: Structure of chromomycin A3 (top) and sequence of the
18-merwith the dimerof chromomycinshownas a rectangle (bottom).

the minor groove of DNA to open, changing it to a structure
which is similar to A-DNA. This conclusion was based on
enhanced cleavage of DNase I, DNase 11, and micrococcal
nuclease at AT-rich sites adjacent to drug binding sites. All
three aureolic acids, chromomycin, mithramycin, and olivomycin, have been studied using hydroxyl radical as a
footprinting probe (Cons & Fox, 1989a,b). The drugs prefer
to bind to the sequence GG via the minor groove of DNA.
Additional insight on the structure of the CHR-DNA
complex has recently been provided by NMR. Gao and Pate1
(1989a,b) showed that, in the presence of MgZ+,CHR binds
as a symmetrical dimer to the self-complementary duplex
d[TTGGCCAA]2 with retention of 2-fold symmetry in the
drug-DNA complex. The two CHR molecules share the
minor groove at the center of the duplex in such a way that
each hydrophilic edge of the chromophore is located next to
a GG site. In addition, the drug-bound duplex appears to
exist in the A-DNA conformation.
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Chromomycin-DNA Complex
For the self-complementaryduplex d[AGGATCCT]2, the
two preferred CHR binding sites, GG, are separated by an
unpreferred site, AT. NMR studies show that, in the presence
of Mg2+,CHR binds as a dimer to this duplex, but the resulting
drug-DNA complex does not have a CZsymmetry axis. This
suggests that binding to the preferred GG site forces half of
the drug dimer to bind to the adjacent nonpreferred AT site
(Gao & Patel, 1990; Leroy et al., 1991).
Other NMRinvestigations (Banvilleet al., 1990a,b) showed
that both mithramycin and chromomycin bind as symmetrical
dimers to the duplex d(ATGCAT)2. The complexes possess
CZsymmetry, and the drug undergoes slow chemical exchange
on the NMR time scale. The fact that NOE contacts exist
between the sugarsof the drug and several deoxyriboseprotons
of DNA suggests that two pyranoses on one side of the aglycon
are oriented along the sugar-phosphate backbone of G3-C4,
while two other pyranoses are located near the backbone of
As-T6. At a molar ratio of 1 drug/duplex, mithramycin
exhibits chemical exchange cross-peaks allowing an estimate
of 0.4 s-l to be made of its off-rate constant. Chromomycin
also binds in a similar manner to the duplexes d[TATGCATA]2 and d[ATAGCTAT]2 but not to the duplex d[ATCGAT12 (Banville et al., 1990a). Binding takes place in a
widened minor groove, in contradiction to the earlier proposed
major-groove model (Keniry et al., 1987).
Although the NMR studies provide a detailed picture of
the CHR-DNA complex, certain aspects of the binding
mechanism remain unresolved. For example, it is not clear
whether the drug binds as a preassociated dimer involving
magnesium or whether it binds as a monomer, followed by
cooperative binding of a second drug molecule to the adjacent
DNA site. At the very low drug concentrations expected in
a cell, one would expect most of the drug to be monomeric,
so that monomers bound to DNA, and not dimers, would
cause the cytotoxicity of chromomycin. In view of the recent
interest in binding between DNA and dimers involving the
aureolic acids and other agents such as distamycin (Pelton &
Wemmer, 1989), we decided to study the CHR-DNA
interaction using quantitative footprinting methods. Since
this technique has the potential for studying binding at drug
and DNA concentrations much lower than those normally
used in NMR studies, it may permit observation of monomer
binding to DNA.
In this report we examine the binding of chromomycin A3
to the duplex d(CAAGTCTGGCCATCAGTC)-d(GACTGATGGCCAGACTTG), Figure 1 (bottom panel), with
quantitative footprinting methods, using as probes DNase I
and dimethyl sulfate (DMS). The 18-mer contains the
sequence 5’-TGGCCA-3’, earlier studied by Gao and Patel
(1989a,b) using NMR methods. We derive information on
whether monomer or dimer is involved in the binding
mechanism from the analyses of the DNase I footprinting
data and fluorescencemeasurements on the drug and its metal
complex in solution. The results of the footprinting experiments with DMS shed light on whether the drug binds to the
major or minor groove and on whether bound drug induces
a structural change in DNA which is detectable with dimethyl
sulfate.
EXPERIMENTAL PROCEDURES

Chromomycin A3 was purchased from Sigma and used
without further purification. Solutions of the drug in ethanol
were stored at 4 OC in the dark until needed. Drug
concentrationswere determined by UV-vis spectroscopyusing
the reported value of c = 39 800 cm-l M-I at 282 nm (Van
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Dyke & Dervan, 1983). All other chemicalswereused without
further purification.
The oligomers d(CAAGTCTGGCCATCAGTC) and
d(GACTGATGGCCAGACTTG) were synthesizedon a 1.Opmol scale by the DNA/Protein Core Facility, Department
of Biology, Syracuse University, using standard 8-cyanoethyl
phosphoramidite chemistry on a DuPont Coder 300 DNA
synthesizer. Typical yields were 250%. Each oligomer was
received with the resin attached and protected at the bases
and phosphate groups of DNA.
Purification of each oligomer was achieved as follows.
Incubation of the sample in 1.5 mL of fresh ammonium
hydroxide at 50 OC for 2 days separated the oligomer from
the resin support and cleaved the 8-cyanoethyl, benzoyl, and
isobutyl protecting groups. Aqueous NaOH was added to a
final concentration of 5 mM, and the sample was evaporated
to dryness. Chromatography using a DuPont Nesorb Prep
cartrigde was used to detritylate the 5’-end of each oligomer
and remove salts, failure sequences, and synthetic byproducts.
For this procedure the DNA was dissolved in 16 mL of 0.1
M triethylammonium acetate (TEAA), pH 7.0, and the
separation was carried out on four 4-mL aliquots according
to the Du Pont method. After washing of the cartridge with
10 mL of MeOH and 5 mL of 0.1 M TEAA, 4 mL of oligomer
was applied to the cartridge. Subsequent washings with 10
mL of 12% CH3CN in 0.1 M TEAA, 25 mL of 0.5% aqueous
trifluoroacetic acid, and 10 mL of 0.1 M TEAA were followed
by elution of the DNA in 10 1-mL fractions using 35% aqueous
MeOH. Oligomer-containing fractions were identified by
determining the absorbance of each solution at 260 nm. The
yield of recovered product was 70%. The solvent was
evaporated to dryness, and each 18-mer was reconstituted in
250 pL of TE buffer (10 mM Tris and 1 mM EDTA), pH
7.6.
To remove contaminating oligomers less than 18 base pairs
in length, aliquots containing approximately 10 OD units of
DNA were loaded onto a 20% polyacrylamide gel containing
6 M urea. After electrophoresis (Sambrook et al., 198q), the
DNA was visualized by backshadowing the gel over a 20-cm
X 20-cm Whatman PK5F silica gel plate containing a
fluorescent indicator and exposing the gel to 254-nm light.
Bands corresponding to the full-length oligomer were excised
from the gel. DNA was recovered by crushing and soaking
the polymer in TE buffer, pH 7.6, at 37 OC followed by
lyophilization. Each oligomer was suspended in 6 mL of water
for desalting with a Waters Sep-Pak C1g cartridge, and the
procedure was carried out on 3-mL aliquots. After rinsing
of the cartridge with 10 mL of CH3CN and 20 mL of water,
3 mL of DNA solution was applied to the cartridge. The
bound oligomer was washed with 10 mL of 25 mM aqueous
ammonium bicarbonate, pH 8.0,lO mL of 25 mM ammonium
bicarbonate, pH 8.0/5% aqueous CH3CN, and 20 mL of 5%
aqueous CH3CN. Product was recovered by elution with 12
mL of 30% aqueous CH3CN. The collected solution was
lyophilized, and each oligomer was dissolved in 300 p L of TE
buffer, pH 7.6. Total product recovery was -25%.
Solutionsof double-strandedDNA were prepared by heating
equimolar amounts of each single-stranded oligomer at 90 OC
for 10min and cooling slowly over 2-3 h to room temperature.
Molar extinction coefficients of 168 000 cm-I M-1 for the
C-rich oligomer and 173 000 cm-1 M-I for the G-rich oligomer
were calculatedfrom reported values for extinction coefficients
of individual nucleotides and the sequence of the oligomer
(Borer, 1975). All DNA solutions were stored at -20 OC.
The C- and G-rich oligomers were labeled at their 5’ ends
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FIGURE
2: Autoradiogram showing DNase I cleavage of the 18-mer labeled at position 1 (C) in the presence and absence of chromomycin
A3. Lane 25 shows cleavage by HueIII, lane 26 shows cleavage by DNase I (no CHR), and lane 27 is DNA alone (no drug or enzyme). Lanes
1-15 show cleavage in the presence of increasing concentrations of CHR in the order listed in Experimental Procedures. The remaining lanes,
16-24. have CHR concentrations in the range 8.92-14.86 uM and were not used in the analysis. A partial sequence of the 18-mer is given
at the'left of the autoradiogram.
v

using [y-32P]ATP/T4polynucleotide kinase and purified via
electrophoresis in a 20% polyacrylamidegel containing 6 M
urea (Sambrook et al., 1989). Solutionsof single end-labeled
double-strandedoligomer with the label at position 1 (C), the
C 18-mer, or position 18 (G), the G 18-mer (see Figure 1,
bottom panel), were prepared by hybridizing the cold strand
to the hot strand in the manner earlier described.
DNase I footprinting reactions were performed on the C
18-mer in a total volume of 12 pL, for 15 min at 37 "C, in
a buffer consisting of 10 mM Tris, pH 7.6,25% ethanol, 0.33
mM EDTA, 8 mM MgC12, and 2 mM CaC12. The footprinting
experiments were performed twice. In the first experiment
the final total drug concentrations present in solution were
0.15,0.30,0.45,0.59,0.74, 1.49,2.23,2.97,3.72,4.46,5.20,
5.94,6.69,7.43, and 8.17 pM. In the second experiment, the
concentrations were 0.1, 0.2, 0.3,0.4, 0.5,0.6,0.7,0.8,0.9,
1.0, 1.2, 1.4, 1.6, 1.8,2.0,2.2,2.4,2.6,2.8,3.0,5.0,
and 10.0
pM. Drug was preincubated with DNA for 2 h at 37 "C prior
to addition of the enzyme. The final concentration of DNA
duplex present in all experiments was 2 pM, and the enzyme
concentration was between 8 X le2
and 8 X l e 3 unit/pL.
Assuming that all of the protein present is DNase I in the
commercial preparation of the enzyme, the concentration of
DNase I present in the various reactions was 10-7-10-8 M.
Reactions were quenched by addition of 6 pL of denaturing
formamideloading buffer (Sambrook et al., 1989) and stored
at -78 "C until the start of electrophoresis. Sequence was
established by HaeIII cleavage of the C 18-mer in a total
volume of 12 pL for 1 h at 37 "C. The final concentration
of DNA was 2 p M in duplex, and the HaeIII concentration
was about 0.21 unit/pL. Aliquots of reactions were heated
to 90 O C and loaded onto 25% (19:l w/w acrylamide/
bisacrylamide) polyacrylamide gels containing 6 M urea. DNA
fragments were separated by electrophoresis at 55 "C using
an in-house-developed electrophoresis device. A Molecular
Dynamics 300A computing densitometer was used to scan
autoradiogramsto yield whole-area spot integrations (volumes)
proportional to DNA concentrations. The autoradiogram for
the first footprinting experiment is shown in Figure 2. The
sum of volumes of all the cleavage products as a function of
drug concentration is shown in Figure 3. Individual spot
intensities as a function of drug concentration (footprinting
plots) are given in Figures 4 and 5 . The autoradiogram for
the second DNase I experiment is shown in Figure 6.
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FIGURE
3: Total-cut plot for first DNase I footprinting experiment
(Figure 2), with linear fit.

In separate reactions, dimethyl sulfate/piperidine footprinting studies were performed using the C 18-mer duplex
labeled at C and G 18-mer duplex labeled at G. These were
done in a total volume of 12pL, for 5 min at 37 "C, in a buffer
consisting of 6 mM Tris, pH 7.6,7.5%ethanol, 0.6 mM EDTA,
and 8 mM MgC12. The final drug concentrations for the
studies involving the C 18-mer were 0.005, 0.01, 0.05, 0.1,
0.5, 1.0 (0.25) 5.0, 10, 15, 25, and 50 pM. The same
concentrations were used for the G 18-mer. Drug was
preincubated with 2 pM of duplex for 2 h at 37 OC,followed
by addition of dimethyl sulfate to a final concentration of
1.7% (v/v). After incubation at 37 OC for 5 min, reactions
were quenched with DMS stop solution (Sambrook et al.,
1989) chilled to 0 "C. To help precipitate DNA samples
during subsequentpurification, 4 mg ( 1 mg/pL) of an aqueous
solution of calf thymus DNA was added. DNA was recovered
by ethanol precipitation as previously described (Sambrook
et al., 1989). Dried samples were incubated in 100 pL of 1
M aqueous piperidine for 30 min at 90 OC. The reaction
products were evaporated to dryness, ethanol-precipitated,
and lyophilized as above. DNA was resuspended in 10 pL of
denaturing formamide loading buffer, heated to 90 "C for 5
min, and electrophoresed in denaturing polyacrylamide gels
as in the DNase I footprinting experiments. The resulting
autoradiograms were scanned with a Molecular Dynamics
densitometer.
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FIGURE5: Experimental footprinting plots for cleavage of sites 5
and 6, with calculated plots (open symbols) from model including
dimer binding and dimerization in solution.

The enzyme possesses a small loop which blocks cleavage
about 3 base pairs to the 3' side of a drug binding site (Suck
& Oefner, 1986). Since the inhibition length is 9 base pairs
long and the loop on the enzyme is 3 base pairs, our results
are consistent with a drug dimer covering the sequence 5'TGGCCA-3' of the 18-mer. The footprinting plots for sites
5 and 6, outside of the drug binding site, do not show inhibition.
Intensities for site 5 , which is farthest from the drug binding
site, are roughly constant with added drug while site 6 shows
a sharp increase near 3 pM drug followed by a decrease after
about 5 pM. Sites 1-4of the 18-mer are not cleaved by DNase
I, because the affinity of the enzyme for the ends of DNA is
low (Suck & Oefner, 1986), and sites 16-17 are weakly
cleaved. Due to their low intensity and proximity of their
spots to the parent band, they were not used in the analysis.
The total cut (sum of intensities for cutting at sites 5-15,
and not including the parent band) for the first DNase I
experiment was plotted against chromomycin concentration
(Figure 3). Since most of the observed sites show decreased
cleavage, the total cut It decreases as drug concentration
increases. It is fit adequately by the linear function It = 20094
- 1617[CHR]. To correct for gel loading and other errors,
all spot intensities for each drug concentration are multiplied
by the ratio of It to the actual total cut for that concentration.
With two exceptions, the correction factors differ from unity
by 12% or less. The resulting intensities are shown in Figures
4 and 5 . The total cut for the second footprinting experiment
(Figure 6) was fit to the linear function I{ = 3595.4 - 239.2[CHR]. Spot intensities for each drug concentration were
corrected using It'. Footprinting plots (not shown) resemble
those for the first experiment.
Enlightening information about binding of drug molecules
to the fragment may be obtained from the initial relative slopes,
calculated by fitting intensities for the first n drug concentrations to a straight line and dividing the slope by the intercept.
The value of n must be large enough to give a significant
variation in intensity but not so large that the footprinting
intensities vary nonlinearly with drug concentration. We have
tried several values of n;the conclusionsdrawn from the initial
relative slopes are the same. Results for n = 11, corresponding
to drug concentrations from 0.1 to 5.2 pM, are shown in Figure
7. The error bars give the uncertainty in each initial relative
slope, calculated from the least-squares fit.
The cleavage inhibition for sites 7-15 is shown clearly by
the negative slopes. The large drug-induced enhancement in
cleavage for site 6 is evidenced by the large positive slope,
while the small slope for site 5 reflects the near-constancy of
the intensity for this cleavage product. Furthermore, we note

-
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FIGURE4: Total-cut corrected footprinting plots (solid symbols) for
drug-blocked sites with theoretical fits (open symbols). Data derived
from Figure 2. Model includes dimer binding and dimerization in
solution.
Fluorescence spectra of chromomycin A3 were recorded on
a Hitachi F-4010 fluorescence spectrophotometer. For measurements in a solvent system consisting of 10 mM Tris buffer,
pH 7.6,0.33 mM EDTA, 8 mM MgC12, 2 mM CaC12, and
25 % EtOH, emission spectra were recorded from 408 to 700
nm using an excitation wavelength of 408 nm. Spectra of
drug solutions in the same solvent system, but without MgC12,
were obtained in the same manner.
ANALYSIS
Establishingthe Model. Examination of the experimental
DNase I footprinting plots (intensity of cut fragment vs total
drug concentration) showed a decrease in cutting with added
drug for sites 7 through 15, ascribed to the classic footprinting
phenomenon: bound drug prevents DNase I from cleaving.

9314 Biochemistry, Vol. 31, No. 38, 1992

II

Stankus et al.

I 1 5 1 1 1 I'PI 1 1 I'PI I 1 12h1 1 I'PI
-T
-A

-C
-C

' e

' G
"T

C.
-T
FIGURE
6: Autoradiogram for DNase I cleavage of the 18-mer labeled at position 1 (C) in the presence and absence of chromomycin A3. Lane
26 shows cleavage by HaeIII, lane 3 shows cleavage by DNase I (no CHR), lane 1 shows DNA alone (no drug or enzyme), and lane 2 shows
DNA alone (no drug or enzyme) heated to 37 "C for a total of 2 h 15 min and then to 90 OC for 5 min according to the footprinting research
protocol. Lanes 4-25 show cleavage in the presence of increasing concentrations of CHR, in the order listed in Experimental Procedures. A
partial sequence of the 18-mer is given at the right.
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FIGURE
7: Relative initial slopes of footprinting plots as a function
of sequence.

that, within the uncertainties due to the scatter in the data,
the slopes may be the same for all sites in the inhibition region.
The inhibition region could result from two monomer binding
sites, such that a drug bound at the first blocks sites 7-12
from cleavage, including 3 base pairs for the loop on DNase
I (Suck & Oefner, 1986), and a drug bound to the second
blocks cleavage at sites 10-15. The fact that initial relative
slopesare the same for all sites means that the binding constants
are not very different for the two binding sites.
Now if there were two monomer binding sites, cleavage at
positions 10-12 would be blocked by drug binding at either
site, and the footprinting intensities for these cleavage sites
would decrease faster with drug concentration than intensities
for cleavagesites blocked by only one drug binding event. The
initial relative slopes show this is not the case, and we can rule
out monomeric binding of drug to the 18-mer. Calculations
for models allowing for independent monomer binding bear
this out: this model cannot fit the data. The sum of squared
deviations between experimental and calculated intensities
(D, eq 1) is greater than 5 X lo6, whereas models including
dimer binding (see below) give D
lo5.
The reason that there is essentially no DNA fragment with
monomer bound could be (1) unbound drug in solution exists
only in the form of dimer or (2) the binding is highly

-

cooperative. In the latter case, the binding constant of a drug
molecule to DNA is much higher when the DNA has already
bound one drug molecule than when no drug is bound, so it
is very unlikely to find a DNA fragment with only one drug
bound. This is the situation for the anticancer drug actinomycin D interacting with the duplex [d(CGTCGACG)]*
(Snyder et al., 1989). To determine whether dimerization of
chromomycinoccurs in solution, we analyzed the footprinting
intensities for sites 7-15 by a model including drug dimerization as well as drug binding.
Let I i j be the spot intensity for the ith site and thejth drug
concentration as calculated from a model. will depend on
one or more nonlinear parameters such as equilibrium
constants. The values of such parameters are obtained by
minimizing the deviation between calculated and measured
intensities:
D=

(1)
ij

For the first data set, for which there are 15 drug concentrations
and 9 sites (only the binding sites are considered), D is a sum
over 135 points. The minimization of D with respect to
nonlinear parameters is carried out by the Simplex procedure
(Fletcher, 1980). By comparing the lowest values of D for
different models applied to the same data set one can judge
whether one model is significantly better than another.
The intensity for spots resulting from cleavage at site i (i
= 7-15) is proportional to the probability that a duplex has
no dimer bound and to the amount of available probe at the
site. Since binding of drug to some duplexes prevents binding
of the cleavageagent, it increases probe concentration in bulk
solution and on duplexes where no drug is bound. When the
rate of cleavage is limited by available probe, the cleavage
may be substantially enhanced. This "mass-action enhancement" (Ward et al., 1988; Goodisman & Dabrowiak, 1992)
may be taken into account by multiplying the calculated spot
intensity by an enhancement factor, calculated by assuming
the amount of probe bound to all DNA sites remains constant
with drug concentration. This implies that the total cut does
not change with drug concentration, as has been observed in
numerous footprinting experiments. However, this does not
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obtain in the present case, as seen in Figure 3, so the massaction model is not usable here. Instead, we consider the
probe-DNA binding equilibria explicitly, as was done previously in treating binding to a single site (Rehfuss et al.,
1990).
The drug-binding equilibria that must be taken into account
are the following:
CHR + CHR F? CHR,

(2)

+ N F? CHR2N

(3)

CHR,

Here, CHR is unbound drug monomer, CHR2 is unbound
drug dimer, N is the 18-mer, and CHR2N is the 18-mer duplex
with bounddrug dimer. Theequilibrium CHR N F? CHRN
is not considered, since [CHRN] is not measurable, and
consideration of this equilibrium would introduce an additional
equation and an additional unknown. The equilibrium between
CHRN, CHR, and CHRNz is a combination of the others.
Binding of Preexisting Dimer to 16mer. We first suppose
the dimerization constant is so large that only dimer is present
in solution; the binding equilibrium, eq 3, is written

+

(4)
where Cb is the concentration of duplexes with dimer bound,
N is the total concentration of oligomers (2 pM), and co is the
concentration of unbound dimers. If ct is the nominal total
drug concentration, expressed as monomer

This could be solved for co for each ct, giving the probability
that a duplex has no drug dimer bound as 1 - cb/N.
We must also consider the probe-binding equilibrium.
Suppose there are n probe sites per oligonucleotide,m of which
are blocked by a bound drug dimer. The n sites include sites
for which cleavage intensities are not measured (i.e., 15-17).
Let u0 be the fraction of oligomers with neither drug nor probe
bound, Ub the fraction with drug alone bound, vi the fraction
with a single probe molecule bound at probe site i ( i = 1-n),
and u j the fraction with a drug dimer bound and a probe
molecule bound at probe site i [ i = ( m 1)-n]. We assume
the foregoingrepresent all the possibilities, so that, for example,
there is never more than one probe bound to a DNA fragment;
therefore, u0 + Ub nul ( n - m ) u j = 1. In terms of eqs 4
and 5 , Cb = Nub ( n - m)Nuj. Assuming that the binding
constant for drug is the same whether or not a probe molecule
is bound to the fragment (at a site from m + 1 to n ) , the
equilibrium equations are

+

+ +

+

K, =

Nub

NU,('/,C,- NU, - ( n - m)Nuf)

--

ui and u j for each value of ct. Then, calculated intensities are

1, = A;ui
for i = l-m and

lij= A,'(Ui + u,')
(8b)
for i = ( m 1)-n. The values of the linear parameters A / ,
which are proportional to digest time and cutting rate
constants, and thus different for different sites, are determined
1 to n will
in the minimization of D. Sites from m
automatically show the mass-action enhancement, if it exists,
since ui and u j are calculated taking into account the probebinding equilibrium.
The nonlinear parameters are K1, Kp,and Pt. In principle,
all could be found from the minimization of D, eq 1, but
because of dependence between the parameters the data are
not sufficiently precise to yield reliable values. One can
estimate Kp as 2 X lo4 M-' (Rehfuss et al., 1990) and Pt as
1X
M (see above) and find only K1 by minimization of
D. The resulting value of K1 is 5.2 X lo6 M-l, with D = 3.0
X lo6. If Pt is fixed at lo-' M and the other two parameters
are varied, we find K1 = 7.1 X lo6 M-l, Kp = 1.2 X lo5 M-l,
andD= 2.4X lo6. If 10-8MisusedforPt,wefindaminimum
Dof 2.3 X lo6 with K1 = 7.1 X lo6 M-l and Kp = 1.1 X lo5
M-l . If Kpis fixed at 2 X 1O4 M-l, variation leads to a minimum
Dof 2 X lo6 with K1 = 7 X lo6 M-l and PI = 3 X lo-* M.
Of course, if both K p and PI are varied (as well as K1) to
minimize D, one can reduce D somewhat, to 1.9 X lo6, but
three variable parameters are now involved, and the decrease
in D is insufficient to place confidence in values for all three
parameters. (The values obtained are K1 = 7.0 X lo6 M-l,
M). Using the
Kp = 1.1 X lo5 M-l, and Pt = 1.4 X
second data set, we find K1 = 2.1 X lo6 M-l by minimizing
D, keeping PI = 5 X
M and Kp = 2 X lo4 M-l. Here,
D is 1.55 X lo5 and its value cannot be reduced much by
changing the assumed values of Kp and PI. With PI = 1 X
l e 7 M, the minimum D is 1.53 X lo5, obtained with K1 =
2.0 X lo6 M-l.
The Drug Monomer-Dimer Association. To consider the
possibility of monomers existing in solution, we introduce the
equilibrium constant K3 which describes monomer-dimer
association outside of DNA, eq 2:

+

+

2

(9)
K3 = co/cm
As before, co is the concentration of drug dimer in solution,
and cm is the concentration of drug monomer in solution. The
equilibrium between unbound drug monomer and drug
monomer bound to DNA is not considered because, as shown
above, bound monomer is of negligible importance. The total
drug (monomer) concentration is now

This model becomes equivalent to the previous one for large
K3. Equation 10 is rewritten as
Nu,'

Nu,('/~c ,NU, - ( n - m)Nu,')
Nui
Kp =
Nuo(Pt- Nnu, - N(n - m)u,')

(6)

(7)

where Kpis the binding constant for probe and PI is the total
probe concentration. The above equations are solved to obtain

co

=

C.L

2

+ (K3c0)-'/' + 2NK1(1 + K1co)-'

and solved iteratively to obtain co for each ct, KI, and K3.
Calculated spot intensities are given by eq 8.
We now minimize D, eq 1, with respect to the two nonlinear
parameters, K, and K3, associated with dimer binding to the
18-mer and the monomer-dimer drug association in solution,
respectively. Again we take PI = 1.O X l k 7 M and K, =: 2.0
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lo4 M-l. We find D = 1.9 X lo6,K1 = 3.5 X lo7 M-l, and
K3 = 6.4 X lo4M-l. The decrease in D from 3.0 X lo6 (found
assuming all drug is in the dimeric form; previous section) is
large, indicating the value of K3 is significant. For the second
data set, variation Of K3 leads to a decrease in D to 1.2 X lo5.
To estimate errors,we find how much K1 or K3 must be changed
to increase D by 10%. This procedure gives, for the first data
set, K1 = (3.5 f 1.8) X lo7 M-l and K3 = (6.0 f 3.0) X lo4
M-l. For the second data set, this procedure gives K1 = (2.3
f 1.5) X 108 M-l and K3 = (4.0 f 3.0) X lo3 M-l. It should
be added that uncertainties in parameters are underestimated,
since, if one changes K1 and K3 simultaneously, their values
can be changed by more than the above, with only a small
change in D.
The self-association constant of chromomycin, K3, is
considerably higher than that found for the anticancer drug
daunomycin, lo2 M-l (Chaires et al., 1982). However, at
concentrationsof <1 pM the drug exists mostly as a monomer
in solution. Thus, the binding of two drugs to the 18-mer is
most likely the result of the binding of one drug followed by
the cooperative binding of a second drug rather than binding
of a preassociated dimer to the duplex.
Analysis of the Fluorescence Data. The monomer4mer
equilibrium can be investigated by fluorescence intensity
measurements. If fluorescence intensity is proportional to
the nominal drug concentration (Beer’s law), it is probable
that only one fluorescent species is present. Deviations from
Beer’s law imply the presence of more than one species, such
as monomers and dimers, in equilibrium with each other in
solution.
Assuming an equilibrium between two monomers and a
dimer, we have

2.4

X

-

c, = c,

+ 2c0

(1 1)
where ct is the nominal drug concentration. Combining eq 11
with the dimerization equilibrium equation (eq 9), we can
solve for cm and CO. Writing the fluorescencedue to monomers
as UmCm and that due to dimers as adCO, we have for the total

f = a , (-1

+ (14:f(K3q)1/2

(

)+
1

+ 4K3ct - (1 + 8K3cJ1/*

)

(12)
8K3
If ad = 2am,f becomes just Umc, independently of 4,but if
&J # 2a,, the deviation from linearity in a plot off vs c yields
information about &. If K3 is small (no dimers) one will have
f amct, while if K3 co (no monomers) one will have f =
intermediate K3 values make f nonlinear in ct. For
small ct, it is appropriate to expand the square roots in eq 12
as power series in ct, giving

-

f = UmCt

+ (ad - ~u,)K~c,Z- 2(ad - 2U,)K:Ct3 + ...

(1 3)
Thus, a fit of experimentalfto a power series in ct will permit
determination of the three parameters in eq 13, am, (Id, and
K3. One could try to fit eq 12 directly, but one would not be
able to assess the effect of increased number of terms as in
the power series.
Figure 8 shows fluorescence intensities at 664.8 nm for
chromomycin concentrations up to 2.8 pM in the absence of
Mg2+ and up to 5.5 pM in the presence of 8 mM Mgz+. In
the latter case, the sum of the squares of residuals is 0.071,
0.031, or 0.030 for linear, quadratic, or cubic fits. Thus, the
intensity is clearly nonlinear in concentration, but the cubic
term is small and hence difficult to determine accurately. The

+Mg2+

g2.11

,,’.

4

e 1.5

d1.24

.
,
,
I

.

,,’

8 0.6

,,’.
,/’

,A

, .

12.,
e 1.5

,i

B

FIGURE8: Fluorescence intensity as a function of nominal drug
concentration, with and without Mgz+. Cubic polynomial fits are
shown.
polynomial coefficients are -0.020, 0.280, 0.0383, and
-0.00241, so that, from eq 13, -2K3 = -0.00241/0.0383 and
K3 = 3.2 X lo4 M-l. However, the uncertainty is large: if
we eliminate the data point for 5.5 pM, the sum of squares
of residuals is reduced to 0.0034, suggesting that this point
is in error. The coefficients are -0.005, 0,110, 0.177, and
-0.0280, which makes K3 = 7.9 X lo4 M-l. This is of the
same size as the value from analyses of the footprinting data.
The effects of Mgz+ on oligomerization of CHR in the
absence of DNA have previously been studied. Hayasaka
and Inoue (1969) used sedimentation equilibrium to show
that, in the presence of Mgz+and high (1 mM) concentration
of the drug, aggregates corresponding to tetramers and
pentamcrs formed in solution, Calcium ion, also present in
the buffer used in the study, apparently has little affinity for
the drug (Itzhaki et al., 1990) and does not facilitate drug
binding to DNA as does Mg2+ (Cons & Fox, 1989a,b).
Fluorescence intensities in the absence of Mg2+(lower plot
of Figure 8) are analyzed in the same way. The sums of
squares of residuals for linear, quadratic, and cubic fits are
0.217,0.039,and 0.012, so the intensitiesareclearly nonlinear
in concentration. The coefficients for the cubic fit are 0.038,
-0.023,0.8936,and 0.173, giving K3= -(-0.173)/ [(2)(0.836)]
= 1.0 X lo5 M-l, essentially the same as, but slightly higher
than, the value derived for Mg2+ present. The plot shows the
cubic fit. K3 is the same with and without MgZ+,to 10%or
so, which is the error in the measurement from fit of data. If
K3 = 1.0 X lo5 M-l, the drug is 85% monomeric at ct = 1 pM
and 53% monomeric at ct = 8.17 p M .
Dimethyl Sulfate Cleavage of the 18-mer. Footprinting
experiments were performed for DMS/piperidine cleavage of
the DNA fragment. Because cleavage by DMS takes place
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Chromomycin-DNA Complex

FIGURE
9: DMS/piperidine footprinting plots for the G 18-mer in
the presence of various concentrations of chromomycin. Dashed
curves show fits to straight lines (using all data, including intensities
for drug concentrations not shown). Slopes divided by intercepts are
as follows: parent band + G18, 0.0010; G6, 0.0095; G10, 0.0152;
G11, -0.0019; G15, -0.0091.
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FIGURE
10: DMS/piperidine footprinting plots for the C 18-mer in
the presence of various concentrations of chromomycin. Dashed
curves show fits to straight lines (using all data, including intensities
for drug concentration not shown). Slopes divided by intercepts are
as follows: parent band, -0.0007; G16, 0.0070; G9, 0.0315; G8,
-0.005; G4, -0.01 16.

in the major groove by attacking N-7 of guanine (Lowley &
Brookes, 1963), while chromomycinbinds in the minor groove,
the classic footprinting behavior (decrease of fragment
intensities with drug concentration) was not expected. However, the possibility existed that bound drug, by inducing a
structural change, would alter DNA cleavage rates by DMS.
For each concentration, all band intensities were divided by
the total intensity to normalize them. This corrects for gel
loading errors, etc., effectively giving a constant total amount
of radiolabeled DNA. The normalized data for each fragment
were then fitted to a linear function of drug concentration.
The normalized data are shown in Figures 9 and 10 with the
linear fits (broken lines). The relative slopes (slope/intercept)
are close to zero in every case. Thus, no alteration in cleavage
rates by drug is evidenced: the cutting rate is unaffected by
drug binding.
From the NMR studies, it has been postulated that
chromomycin binding alters DNA structure to A-DNA (Gao
& Patel, 1989a,b, 1990; Leroy et al., 1991). This form of
DNA is characterized by a wide and shallow minor groove
and a narrow but deep major groove (Dickerson et al., 1982).
Since changes in DNA structure have been reported to

influence the alkylation rate of DMS (Nielsen, 1990),
chromomycin binding to the 18-mer may affect the alkylation
rates at the guanines located at positions 8-1 1 of the duplex.
As is shown in Figure 10, the normalized bond intensities for
cleavage at all guanine sites on the 18-mer labeled at C show
no change in intensity as drug is added to the system. Since
the DNase I footprinting studies established that drug binding
is taking place, either there is no drug-induced structural
change in DNA or there is a change but, under the conditions
of the experiment, DMS cannot detect the change.
Implicationsfor the Mechanism ofActionof Chromomycin.
It is interesting to compare the footprinting-derived binding
constants with others in the literature. Behr et al. (1969) and
Nayak et al. (1973) used absorption spectroscopy and
Scatchard analysis to measure the binding constant of
chromomycin toward calf thymus DNA. The values obtained,
(0.92-2.0) X lo5M-I, agreed with that recently measured for
the related drug mithramycin using fluorescencespectroscopy.
Chromomycin is also able to bind to chromatin but with a
binding constant about an order of magnitude lower than for
binding to calf thymus DNA (Nayak et al., 1975). While
most of the reported values lie in the range 104-105 M-l,
Itzhaki et al. (1990) reported an unusually high value of 10"
M-I. This value was obtained by recording the optical changes
which occur when EDTA is used to break up the chromomycinMg*+-DNA complex in solution. The reason that our
footprinting measurements return a binding constant 2 orders
of magnitude higher than most other determinations is unclear.
However, footprinting directly measures the fraction of a DNA
site blocked by drug whereas in spectral titrations this quantity
is inferred from the optical properties of the species present
in solution. Since there may be a number of chromomycin
species present in solution, it is dangerous to use only optical
methods to measure the drug's affinity. In addition, the
binding constant to calf thymus DNA is an average over many
binding sites, whereas the present studies consider a fragment
which is known to possess only a single strong binding site.
This site is unusual in the sense that it can bind two drugs
symmetrically, a situation that is not often encountered in
random sequence DNA. The footprinting and fluorescence
data indicate that, at the submicromolar concentration of
chromomycin expected in the cell, the drug probably exists
as a monomer in solution. It is unclear if the drug is complexed
to ions or free in vivo. However, the high concentration of
Mg2+in the serum and cytoplasm suggests that a magnesium
complex is likely under cellular conditions. Since most
potential chromomycin binding sites on natural DNA would
not have 2-fold symmetry, it would appear that monomer and
not dimer binding is the mode by which the drug expresses
its antitumor properties. In this regard, monomer binding
can clearly be seen in the early footprinting studies by Van
Dyke and Dervan (1983) using Fe-MPE as a cleavage agent.
However, as has been shown in our footprinting experiments,
a DNA sequence having adjacent chromomycin sites can bind
two drug molecules with a binding constant 2 orders of
magnitude higher than that found for other sites in random
sequence DNA. Thus, dimer binding may be an important
event in vivo, especially in the promoter regions of genes, which
are often rich in GC content. An understanding of the form
of the drug which is present in vivo is a necessary first step
for understanding the drug's cytotoxic and immunosuppressive
properties. Determining which of many potential binding sites
in gene sequences will be bound by chromomycin will require
additional study.
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CONCLUSIONS

In this manuscript we show that two chromomycin A3
molecules bind to an oligonucleotide duplex having 2-fold
symmetry, with a binding constant several times lo7M-l. The
DNase I footprinting and fluorescence data show that the
self-association constant for the drug outside of DNA is large,
lo5M-1. However, at micromolar concentrations, the drug
exists mainly as a monomer and binding of two drugs to the
duplex takes place in a cooperative manner. Quantitative
footprinting studies with dimethyl sulfate, which alkylates at
N-7 of guanine located in the major groove, failed to detect
a structural change in DNA in the chromomycin complex.
The enhanced affinity of the drug for the 2-fold symmetric
site suggests that sites of this type may be bound by drug in
vivo. The results of this study, at an earlier stage of analysis,
have been previously published (Dabrowiak et al., 1992).

-
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